Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with advanced ovarian cancer (not a type called carcinosarcoma), primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue or cell sample, and have already received at least one round of platinum-based chemotherapy (for ovarian cancer participants)
- You have been diagnosed with endometrial (uterine) cancer that has come back or gotten worse after receiving both immunotherapy (anti-PD-1) and platinum-based chemotherapy (for endometrial cancer participants)
- You have at least one tumor that can be measured on a scan (for certain groups within the trial)
- Your blood test shows a specific cancer marker called CA-125 is raised above a certain level (for ovarian cancer participants; confirm with trial site)
- Your heart, liver, kidneys, and bone marrow are functioning well enough as set out by the trial (confirm with trial site)
- You are able to carry out daily activities with no or minimal limitations, based on a standard health scale (score of 0 or 1)
- Your doctors expect you to live for at least 3 more months
Who may not be able to join:
- You are currently receiving, or have recently received, another experimental treatment, a biological therapy, or cancer immunotherapy
- You have had another type of cancer in the last 5 years that is still active, needs treatment, or is likely to come back
- You have previously been treated with a therapy that targets a protein called MUC16
- You have received more than 5 different rounds of systemic (whole-body) treatment (for certain ovarian cancer groups only)
- You need to take steroid (corticosteroid) medicines on a regular, ongoing basis
- You have a significant autoimmune disease that needed treatment with medicines that suppress the immune system, either currently or within the last 5 years
- You have untreated or currently active cancer that has spread to the brain or spinal cord
- You have a history of serious heart or blood vessel disease (confirm with trial site for specific conditions)
- You have a known allergy or bad reaction to the study drug cemiplimab or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose Limiting Toxicities (DLT); Incidence of DLTs; Incidence of Treatment-Emergent Adverse Events (TEAEs); Incidence of Serious Adverse Events (SAEs); Incidence of deaths; Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0]); Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab; Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.